LEWISVILLE, Texas–(BUSINESS WIRE)–Orthofix International (NASDAQ: OFIX) announces the full market
release of Collage™ Osteoconductive Scaffold, a new bone graft substitute, for
use in spine and orthopedic indications, at this weeks North American Spine
Society (NASS) meeting to be held in Chicago, Illinois.
“We are proud to announce the launch of Collage, our new
synthetic platform based on highly-purified biocompatible materials of ß-TCP
and type-1 collagen,” said Michael Finegan, President of Biologics. “We have
been tremendously successful with Trinity Evolution and can now focus on
broadening our portfolio of biologic products so that we can fulfill all the
needs of our customers. The synthetic segment of the market is large,
attractive, and presents a perfect complement to our existing biologic
portfolio.”
The U.S.
market for synthetic bone graft substitutes is estimated to include more than
320,000 procedures and is valued at approximately $360 million annually,
according to a recent iData Research report.
About Orthofix
Orthofix International N.V. is a global medical device company offering a broad
line of minimally invasive surgical, and non-surgical products for the spine,
orthopedics, and sports medicine market sectors that address the lifelong
bone-and-joint health needs of patients of all ages helping them achieve a more
active and mobile lifestyle. Orthofixs products are widely distributed around
the world to orthopedic surgeons and patients via Orthofixs sales
representatives and its subsidiaries, including BREG, Inc., and via
collaborations with other leading orthopedic product companies. In addition,
Orthofix is collaborating on R&D activities with leading research and
clinical organizations such as the Musculoskeletal Transplant Foundation, the
Orthopedic Research and Education Foundation, Texas Scottish Rite Hospital for
Children, and the Cleveland Clinical Foundation. For more information about
Orthofix, please visit http://www.orthofix.com.
